Advertisement Pharmaceutical Business review - Page 458 of 5276 -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
June 9, 2026

J&J to acquire Firefly Bio for $1bn to enhance oncology pipeline

Johnson & Johnson (J&J) has agreed to purchase Firefly Bio for $1bn in cash, aiming to strengthen its oncology pipeline with Firefly Bio’s proprietary Firelink degrader-antibody conjugate (DAC) platform.

Firefly Bio is focused on advancing its Firelink DAC platform in cancer indications where treatment options remain limited. Credit: Michael Vi / Shutterstock.com.